secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K/A
Filed at:   2025-11-21T23:59:59+00:00
Accession:  0001437749-25-036005
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.40
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals amends 8-K to provide acquired Dura Medical's FY2024 financials
--------------------------------------------------------------------------------

- Acquisition of Dura Medical closed September 8, 2025; this amendment provides required financials.
- Dura Medical FY2024: net patient revenue $3.26M, net income $505K, total assets $1.37M.
- Dura Medical for six months ended June 30, 2025 (unaudited) also provided.
- Pro forma combined financials filed; reflects impact of acquisition on NRx statements.
- Audited by Weinberg & Company; no material adjustments noted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925036005/0001437749-25-036005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925036005/nrxp20251118_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-036005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer